Sterility

Sterility is defined as the absence of viable contaminating microorganisms.

For all injectable (parenteral) drug products, sterility is an absolute requirement and a critical quality attribute essential for patient safety. The sterility test confirms that the drug product is free from bacteria, yeast, and fungi, thereby preventing  life-threatening infections upon administration.

True sterility assurance is achieved through a robustly designed, validated, and meticulously controlled aseptic manufacturing process. 

• Extended Incubation Period: The 14-day compendial test delays product release and is particularly challenging for short-shelf-life products.

   

• Method Suitability (B/F Test): Mandatory validation to demonstrate that the product matrix does not inhibit microbial growth.

   

• False Positives: The aseptic nature of the assay makes it vulnerable to contamination from laboratory handling or the environment, which can trigger costly investigations.

   

• Emerging RMMs: Novel rapid methods (e.g., ATP bioluminescence, flow cytometry, molecular amplification) are being developed to shorten release timelines.

The requirement for a fully validated sterility test according to pharmacopeial standards (e.g., USP <71>) applies across all phases of development for parenteral products. There is little to no flexibility on this requirement. From the first clinical trial to commercialization, the product must be demonstrated to be sterile using a suitable and validated method.

• Patient Risk: High. Injecting a non-sterile product can introduce microorganisms directly into the bloodstream, leading to sepsis, a life-threatening systemic inflammatory response which can cause organ failure and death.
• Manufacturing Risk: A confirmed sterility failure is one of the most serious cGMP deviations. It indicates a critical breach in the aseptic manufacturing process or container closure system. This results in batch rejection, a potential recall, and a comprehensive investigation that can lead to a facility shutdown.

• Bioburden: Sterility testing provides final confirmation of aseptic process success. Bioburden, which is the population of viable microorganisms on or in a product before the final sterilization step (e.g., sterile filtration), is the key in-process control. A high bioburden result is a major risk factor for a final sterility failure.
• Container Closure Integrity: A sterility failure that occurs during a stability study is a direct indicator that the Container Closure Integrity of the vial or syringe has been compromised, allowing microbial ingress.

The 14-day sterility test is widely recognized as a limitation for modern therapies. Regulators and industry are actively advancing Rapid Microbiological Methods (RMMs) to reduce release timelines to days or hours. This is particularly important for cell and gene therapies with limited shelf life.

• Compendial Requirement (USP <71>): This chapter is the definitive regulatory standard for sterility testing in the United States. It details the required test methods, media, incubation conditions, and validation requirements. Compliance is mandatory.
• Method Suitability: Regulators require a robust Bacteriostasis and Fungistasis (B/F) study for each specific product to prove that the product matrix does not invalidate the test by inhibiting the growth of potential contaminants.
• Aseptic Processing Guidance: FDA and other regulatory guidance on aseptic processing provide the framework for how to manufacture a sterile product, which is the ultimate goal that the sterility test is designed to confirm.